Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.46 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 2/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1462408 | 0.92 | MBTD1 (0.41) | MBTD1L3MBTL3L3MBTL1EPAS1 | |
| SCHEMBL16281659 | 0.92 | MBTD1 (0.41) | MBTD1L3MBTL3L3MBTL1EPAS1 | |
| Hydrochloric Acid SCHEMBL4068811 | 0.88 | MBTD1 (0.39) | MBTD1L3MBTL3L3MBTL1EPAS1 | |
| SCHEMBL1317662 | 0.86 | — | — | |
| SCHEMBL9142378 | 0.85 | MBTD1 (0.40) | MBTD1L3MBTL3L3MBTL1NOS2NOS3 | |
| SCHEMBL2273760 | 0.85 | MBTD1 (0.40) | MBTD1L3MBTL3L3MBTL1NOS2NOS3 | |
| SCHEMBL90804 | 0.83 | MBTD1 (0.44) | MBTD1L3MBTL3L3MBTL1EPAS1NOS2 | |
| Hydrochloric Acid SCHEMBL5242922 | 0.83 | — | — | |
| SCHEMBL4069679 | 0.83 | MBTD1 (0.32) | MBTD1L3MBTL3 | |
| SCHEMBL22915706 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3424929-A1 | PYRIMIDINE SEVEN-MEMBERED-RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | Anhui New Star Pharmaceutical Development Co., Ltd (CN) | 2019-01-09 | — | — | EP | claimed |
| CN-105413397-A | Compound absorbent for removing CO2 from tail gas | SINOPEC ENERGY ENV PROT ENG SCIENCE & TECH CO LTD | 2016-03-23 | — | — | CN | claimed |
| US-10961225-B2 | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-03-30 | — | — | US | disclosed |
| US-20200325118-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | NXERA PHARMA UK LIMITED (GB) | 2020-10-15 | — | — | US | disclosed |
| CN-109996790-A | Piperazine carbamate and its preparation and application | 阿比德治疗公司 | 2019-07-09 | — | — | CN | disclosed |
| CN-105413397-A | Compound absorbent for removing CO2 from tail gas | SINOPEC ENERGY ENV PROT ENG SCIENCE & TECH CO LTD | 2016-03-23 | — | — | CN | disclosed |
| US-20100130513-A1 | BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS | ISIS PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130513-A1 | BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS | ISIS PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| CN-101553481-A | Substituted sulfonamide derivatives | GRUENENTHAL GMBH (DE) | 2009-10-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325118-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | CHRM1, CHRM2, CHRM4 | MBTD1 655/4885L3MBTL3 4206/4885L3MBTL1 3372/4885 |
| US-20100130513-A1 | BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS | ZC3HAV1, NXF1, ZC3HAV1L | MBTD1 1179/4885L3MBTL3 1935/4885L3MBTL1 1092/4885 |
| US-10961225-B2 | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor | CHRM1, CHRM2, CHRM4 | MBTD1 655/4885L3MBTL3 4206/4885L3MBTL1 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.